肿瘤细胞治疗研究
FRONTIER PAPERS
N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.
这些发现表明，非恶性 TME 细胞表达的 N-聚糖抑制了 CRC 和 PDAC 中的 CAR-T 细胞反应，突显了 MGAT5 依赖性分支作为一个潜在可干预的轴心，并支持 N-糖基化通路多个节点发挥更广泛的作用。
Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer.
C9-66 CAR-T 细胞经代谢优化与 TME 重编程，代表一种肿瘤特异性、可临床转化的免疫治疗策略，适用于 PDAC 及其他表达 ofCS 的实体瘤。
The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance.
Real-time monitoring of CAR T cell dynamics in tumor patient-derived organoids using the OrganoIDNet algorithm.
通过将类器官-免疫共培养与 OrganoIDNet 驱动的活细胞成像相结合，我们建立了一种自动化纵向成像检测方法，用于评估 PDAC PDO 中 CAR-T 细胞介导的反应。该检测方法能够在多个效靶比下连续定量类器官数量和面积，并结合基于图像的 T 细胞邻近性评估。这些测量提供了观察期内抗原依赖性细胞毒作用和空间关联的时间分辨信息，支持其作为 CAR-T 细胞开发和未来个性化免疫治疗研究的临床前平台的潜在用途。
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".
STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer.
我们的研究结果提示，STING 缺陷的 CAR-T 细胞有望从 STING 激动剂中获益，以改善对胰腺癌等免疫匮乏型癌症的 CAR-T 细胞治疗。
Ablation of prostaglandin E(2) signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.
Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors.
IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.
RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma.
瘤内 RIG-I 预激重编程 PDAC 肿瘤微环境，将无应答的肿瘤转变为允许 CAR-T 发挥作用的肿瘤，从而支持持久的多抗原免疫。
MEMBER ACCOUNT
登录成功会直接打开下一页。
